UK Scientists Race to Develop Ebola Vaccine for the Rare Strain Now Spreading Across Central Africa
When the World Health Organization declared the latest Ebola outbreak in the Democratic Republic of Congo a public health emergency of continental security, the world’s attention turned — once again — to the devastating capacity of a virus that has haunted central Africa for decades. But beneath the familiar urgency lies an unfamiliar problem: the strain driving this outbreak has no licensed vaccine, and the clock is ticking.
UK scientists announced this week that they are accelerating work on a vaccine candidate specifically targeting the Bundibugyo strain, a rare and particularly lethal variant first identified during an outbreak in the DRC in 2007. The team, working across multiple British universities and research institutions, says it aims to have a candidate ready for early human trials within months — a timeline that, if achieved, would represent unprecedented speed in vaccine development.
Why This Strain Is Different
Most of the world’s existing Ebola vaccines — including the rVSV-ZEBOV shot that proved effective in the 2014–2016 West African crisis and in subsequent outbreaks — were designed to target the Zaire strain, the most lethal and most commonly circulating variant. Bundibugyo is a different animal. It behaves differently immunologically, which means the existing vaccines offer little to no cross-protection.
The fatality rate for Bundibugyo can reach up to 70 percent in some community settings, and the current outbreak has already recorded nearly 600 suspected cases across DRC and Uganda, with 148 suspected deaths. The fact that it has spread across borders — with confirmed cases now in Uganda — has added urgency to the search for a dedicated countermeasure.
A Timeline of Urgency
The scientists involved say the development process that normally takes years is being compressed into months without shortcuts on safety. The approach involves using modern genomic sequencing to rapidly characterize the Bundibugyo strain’s surface proteins, then engineering a vaccine construct that trains the immune system to recognize those specific targets.
Phase 1 human trials — which test for safety and immune response in a small group of volunteers — could begin before the end of the year if regulatory approvals are expedited. Typically, such trials require extensive pre-clinical validation and months of review. The team is seeking emergency use pathways similar to those that compressed the COVID-19 vaccine timeline, though they are careful not to promise what they cannot deliver.
Community Trust Remains a Major Hurdle
Even if a vaccine is ready in record time, experts say the bigger battle may be fought on the ground. The outbreak in Ituri province is occurring in an active conflict zone where community distrust of health responders runs deep. During the 2018–2020 Ebola outbreak in North Kivu — the second deadliest in recorded history — hundreds of health centres were attacked, sometimes by armed groups, sometimes by civilians who believed the response was part of a broader scheme against them.
More recently, an angry crowd in Rwampara set fire to an Ebola treatment centre, destroying tents and a body scheduled for burial. At least two Red Cross volunteers have died from suspected Ebola while on active response duty. In such an environment, bringing a vaccine — no matter how well-designed — to the people who need it most will require far more than a laboratory breakthrough.
The Continent’s Health Sovereignty Gap
The race to develop a Bundibugyo vaccine shines a harsh light on a long-standing imbalance in global health research: diseases that disproportionately affect Africa are chronically underfunded and under-researched. The Bundibugyo strain has been known to science since 2007, yet two decades of neglect meant that when the current outbreak began, there was no ready-made solution waiting in the wings.
Africa CDC has convened emergency meetings and called for accelerated international cooperation, but the broader question raised by this outbreak is whether the continent can build the research and manufacturing capacity to respond to its own health emergencies — without waiting for external beneficence to arrive on a timeline set elsewhere.
For now, UK scientists are working at pace. Whether the doses will arrive in time — and whether communities will accept them — is the question the coming months will answer.
